Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lycera has achieved the first milestone under its research collaboration with Merck, triggering a milestone payment.
Subscribe to our email newsletter
The collaboration is focused on developing potential drug candidates to treat major autoimmune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and multiple sclerosis.
In March 2011, the companies entered into a research collaboration to discover, develop and commercialize small molecules that target T-helper 17 (Th17) cells, key mediators of inflammation.
Lycera president and CEO Kathleen Metters said the achievement demonstrates the team’s progress in moving the program forward to develop novel, oral medicines for the treatment of autoimmune diseases.